Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Nerdwallet Inc (NRDS) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Nerdwallet IncTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Nerdwallet Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Nerdwallet Inc trades at $9.17 (market cap $616.53M). The key difference: Ginkgo Bioworks Holdings Inc and Nerdwallet Inc are close in size by market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.

DNANRDS
Market Cap
$590.53M$616.53M
Sector
HealthFinancials
52-Week High
$16.14$15.93
52-Week Low
$5.48$7.58
Enterprise Value
$627.78M$530.83M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.

The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.49, up 0.21% today, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported revenue of $836.6M in 2025, with net income of $48.7M and a net margin of 5.82%, showing a clear turnaround from losses in prior years. Recent earnings beats, including Q1 2026 EPS of $0.29 versus $0.25 expected, underscore operational strength. Analyst consensus is bullish with a $12.75 price target, implying 34% upside.

The outlook is positive given valuation multiples like a P/E of 10.2 and EV/EBITDA of 3.87, which appear attractive relative to growth. Key risks include reliance on search-driven traffic and macroeconomic sensitivity. Continued execution on revenue diversification and cost control supports further upside, but investors should monitor competitive pressures and consumer spending trends.

Returns comparison

Trailing returns across standard periods

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS